VNDA

Vanda Pharmaceuticals Inc. - Common Stock (VNDA)

About Vanda Pharmaceuticals Inc. - Common Stock (VNDA)

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Details

Daily high

$4.60

Daily low

$4.48

Price at open

$4.53

52 Week High

$6.36

52 Week Low

$3.81

Market cap

264.6M

Dividend yield

0.00%

Volume

797,913

Avg. volume

379,471

P/E ratio

-5.93

Vanda Pharmaceuticals Inc. - Common Stock News